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Purpose: To compare outcome after carotid endarterectomy (CEA) in patients who would have been excluded from the
North American Symptomatic Carotid Endarterectomy Trial (NASCET) or the Asymptomatic Carotid Atherosclerosis
Study (ACAS) or would have been eligible for Acculink for Revascularization of Carotids in High Risk Patients
(ARCHeR), a current high-risk stent registry, with outcome in a similar cohort at low risk.
Methods: Records of all CEAs performed at our institution from July 1993 to December 2000 were reviewed. Patients
were assigned to groups either eligible or ineligible for NASCET and ACAS or ARCHeR, and criteria were stratified
according to whether risk was defined by anatomic or medical problems or whether patients were ineligible according to
nonmedical protocol exclusion criteria only.
Results: Preoperative and postoperative data were sufficient to determine risk status according to various study criteria in
857 patients. Stroke or death within 30 days, the primary end point, occurred in 2.1% of patients. Rates were similar in
patients excluded from (2.7%) or included in (1.6%) NASCET and ACAS and in patients eligible (3.1%) or ineligible
(2.1%) for ARCHeR. Rates did not differ according to whether exclusion or inclusion was based on anatomic risk, medical
risk, or protocol exclusion, although trends favored worse outcome in the ARCHeR medical risk subgroup. A higher rate
of minor complications was found in the elderly; however, stroke and death rates were similar according to age, gender,
repeat procedure, or the presence of contralateral occlusion.
Conclusions: No statistically or clinically significant differences were found in combined 30-day stroke or death rates after
CEA in any group defined by previous surgical trials or current ongoing high-risk stent registry. While high-risk groups
may exist, the premise that operative risk is higher in patients excluded from NASCET and ACAS or eligible for ARCHeR
is not supported. (J Vasc Surg 2003;37:575-81.)
A great deal of interest and attention has recently been
directed toward angioplasty and stenting of lesions in the
carotid artery bifurcation. Early results have not been en-
couraging, with combined stroke and death rates after
carotid artery stenting in the 7% to 12% range,1-6 but results
of recent series from centers that perform a high volume of
such procedures reflect both improved outcome7 and fa-
vorable learning curves.5,6 Some believe prospective ran-
domized trials are appropriate, although it has also been
proposed that carotid artery stenting be reserved only for
patients with carotid lesions at high risk.8,9
The definition of high risk varies considerably, espe-
cially between proponents of surgical versus endovascular
therapy for carotid disease. The decision as to when to
operate is best supported by data from the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)10
and the Asymptomatic Carotid Atherosclerosis Study
(ACAS).11 Many surgeons use these data indiscriminately,
but it is important to recognize that many patients were
excluded from one or both trials on the basis of a variety of
criteria. This has been cited by some to define high risk and
hence suitability for stenting,12 but not all agree that this
premise is valid. The current study was designed to deter-
mine whether patients operated on at our institution who
would have been excluded from NASCET or ACAS or
been eligible for Acculink for Revascularization of Carotids
in High Risk Patients (ARCHeR), an ongoing registry of
patients at high risk, are indeed at high risk for stroke and
other complications after conventional carotid endarterec-
tomy (CEA).
METHODS
We identified all patients undergoing elective CEA at
our institution from July 1993 to December 2000. Office
charts were reviewed to determine indications for surgery
and risk factors as described below, and inpatient charts
were reviewed to determine perioperative morbidity and
mortality. Because these groups seem unique, patients were
excluded if they underwent combined coronary artery by-
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pass grafting (CABG) and CEA or were operated on be-
cause of acute evolving stroke, dissection or a traumatic
lesion, or had a known arch or inflow lesion that required
planned correction. Procedures were included only if data
were available to accurately assess inclusion and exclusion
criteria. Because not all patients were thus eligible for this
analysis, the charts of all patients with any record of stroke
or death were reviewed for gross outcome, and data were
analyzed to ensure that the study group was representative
of the entire population.
Two sets of high-risk criteria were used: those that
would have excluded patients from NASCET or ACAS and
those that would have included them in ARCHeR. In
addition, several factors variously suggested as increasing
risk were individually analyzed without reference to specific
study protocols. NASCET and ACAS exclusion criteria
were derived from the respective primary reports10,11 and
the recent analysis by Lepore et al.13 The various high-risk
criteria were stratified according to whether they were due
to challenging anatomy (anatomic risk factor, eg, recurrent
lesion), high medical risk (medical risk factor, eg, severe
cardiac dysfunction), or simply protocol exclusion (proto-
col risk factor, eg, factors confounding analysis, such as
atrial fibrillation or an existing deficit). When competing
high-risk symptoms existed between ACAS and NASCET
(eg, symptoms or percent stenosis), the more inclusive of
the two was used. Warfarin sodium (Coumadin) use was
judged to be a protocol exclusion rather than a medical
exclusion, and age older than 80 years and recent contralat-
eral CEA were judged to be medical exclusions. For clarity
of analysis, each factor was considered in one category only
(Table I).
Stroke was defined as any neurologic event of any
severity lasting longer than 24 hours occurring from the
time of angiography, if performed, to 30 days after surgery.
Regardless of the diagnosis when surgery was performed,
true global hypoperfusion was deemed present only if
global symptoms such as significant and recurrent dizziness
or syncope were present in the setting of at least bilateral
significant carotid stenosis and resolution of symptoms
occurred after CEA. If angiography was not performed, a
“high” bifurcation was defined by specific mention in the
Table I. High-risk criteria
NASCET/ACAS exclusion 10,11,13 ARCHeR inclusion
Anatomic Prior carotid endorterectomy Prior carotid endorterectomy




Contralateral recurrent laryngeal nerve paralysis
Medical Age greater than 80 y
Contralateral CEA within 4 mo
Contralateral occlusion
Two or more of the following:
Uncorrected 2-vessel coronary artery disease
Unstable angina Unstable angina
Surgery needed within 30 d
Myocardial infarction within 6 mo of visit Myocardial infarction within 30 d
Symptomatic congestive heart failure Severe left ventricle dysfunction (ejection fraction 30%)
Significant valve disease
Lung, liver, or renal failure Undergoing dialysis
Listed for organ transplantation
Uncontrolled hypertension or diabetes mellitus Uncontrolled diabetes mellitus
Protocol Tandem lesion higher than bifurcation
Stenosis less than 30% or artery occluded
Unable to consent
Other lesion that could cause symptoms
Previous cerebrovascular accident with profound
deficit
Contralateral symptoms within 45 d
Nonhemispheric symptoms
Major surgery within 1 mo
Atrial fibrillation
Cancer with 50% 5-y survival
Aspirin allergy or active ulcer
Warfarin sodium use
High-risk factors defined by variables that would have excluded patients from NASCET or ACAS or included patients in ARCHeR (see text). Anatomic
variables are those judged to make surgery more difficult; medical, those making surgery more risky; and protocol, those that exclude a patient because of
difficulties in enrollment or assessing outcome.
NASCET, North American Symptomatic carotid endarterectomy Trial; ACAS, Asymptomatic carotid Atherosclerosis Study; ARCHeR, Acculink for
Revascularization of Carotids in High Risk Patients.
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operative note of difficulty in exposure because of high
dissection. No patient had spinal immobility. Finally, cor-
onary valve disease was deemed significant if symptoms
most logically resulting from the valve itself were present.
The primary end point was the occurrence of either
stroke or death during this interval; all neurologic events,
including significant cranial nerve injury and transient isch-
emic attack, and other complications were also recorded.
Postoperative hemodynamic disorders were judged minor
if simply noted in the chart or treated on the floor, and
major if transfer to the intensive care unit or delay in
discharge was required. Major cranial nerve injuries were
defined as symptomatic injury to the hypoglossal, glosso-
pharyngeal, or vagus nerve. Each category of risk factor
(anatomic, medical, protocol) was evaluated indepen-
dently. Statistical analysis was performed with Statview
5.0.1 (SAS Institute, Cary, NC). Comparison of discrete
variables between groups was performed with the Chi-
square and Fisher exact tests, depending on cell size.
RESULTS
From July 1993 to December 2000 at our institution,
1377 CEAs were performed in 1287 patients who met the
criteria described above. Nine surgeons contributed cases
to this series. Our policy toward both angiography and
anesthetic technique changed dramatically during this in-
terval. While overall rate for preoperative angiography was
21% and for general anesthesia was 83%, use of angiography
declined from 83% to 12% and use of cervical block anes-
thesia increased from less than 1% to 38% in 1993 versus
2000, respectively. Indications for CEA were conventional.
Determination of stenosis was made with conventional
duplex ultrasound scanning, and surgery was reserved for
patients with symptomatic stenosis of at least 50% or
asymptomatic stenosis of at least 80%. We performed
largely conventional CEA with patch closure during this
study, although in recent years we have used eversion
endarterectomy preferentially, and inserted a shunt selec-
tively based on electroencephalographic or neurologic
monitoring.
After reviewing inpatient and outpatient charts, data
judged reliable enough for analysis, including indication for
surgery, risk factors, and 30-day outcome, were available
for 859 of the 1377 CEAs. The most common reasons for
complete data unavailability were poor documentation of
risk factors (n  371) and difficulty in locating archived
charts (n 147). Overall outcome after all procedures with
any data available was similar to that in procedures with
enough data for full analysis (Table II). Overall results
according to indications for surgery are presented in Table
III, and complications are shown in Table IV.
Outcome according to NASCET or ACAS exclusion
criteria are presented in Table V. No significant differences
existed when any group of excluded patients was compared
with those included according to the same criteria. In many
cases there was a trend toward higher complication rates in
patients at high risk who were excluded, but in no case were
differences significant, even when only patients excluded
because of medical or anatomic reasons were considered
together.
Outcome according to ARCHeR inclusion criteria are
presented in Table VI. Again, no significant differences
existed when comparing patients at high risk versus those at
low risk, although there was a trend favoring a higher
complication rate in patients considered to be at high risk
because of medical conditions (4.6% vs 2.0%; P  .11). If
only those patients with significant neck problems (eg,
stoma or previous irradiation therapy) or severe cardiac
disease (n  18; 2.2% of total patients) are considered,
however, risk is numerically higher (11.1% vs 2.1%), al-
though, again, statistical significance is not reached.
Finally, several factors that have been proposed to
influence the risk for CEA were individually analyzed,
against their absence, in each case (Table VII). There was a
higher overall complication rate in patients older than 80
years (40.5% vs 30.4%; P  .02), largely the result of
increased incidence of urinary retention and falls. A higher
proportion of elderly patients underwent CEA with cervical
block rather than general anesthesia (23.8% vs 14.9%; P 
.03), but selection criteria and thus influence on outcome
Table II. Stroke and death: Partial vs full results available





(n  859) P
Stroke 2.0 1.7 .64
Death 0.6 0.5 .75
Stroke or death 2.4 2.1 .61
Thirty-day outcome in 1230 patients in whom stroke or death outcome data
were available compared with 859 with enough data to allow analysis of
NASCET and ACAS exclusion criteria and ARCHeR inclusion criteria. No
differences were formed at Chi-square analysis.
NASCET, North American Symptomatic Carotid Endarterectomy Trial;
ACAS, Asymptomatic Carotid Atherosclerosic Study; ARCHeR, Acculink
for Revascularization of Carotids in High Risk Patients.






All patients (n  859) (%) 32.1 2.1
Asymptomatic (n  461) (%) 34.0 2.2
Transient ischemic attack or
amaurosis fugax (242)
31.5 1.3
Recent stroke (n  53) 27.9 4.6
Within 3 wk (n  28) 30.4 8.7
3-6 wk (n  25) 25.0 0.0
Stroke 6 wk (n  33) 17.9 0.0
Nonhemispheric (n  62) 37.5 4.2
Crescendo transient ischemia (n  8) 25.0 0.0
All patients analyzed during the study period, with rates of all complications
and stroke or death within 30 days reported according to initial symptom.
Only patients operated on because of stroke were classified as stroke 6
weeks.
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are not clear. Modest increases in substantial hemodynamic
problems and nonfatal cardiac complications were also
seen, but no factor reached statistical significance. No dif-
ferences in overall neurologic event or stroke rate or in
death rate were seen. Trends toward higher overall compli-
cation and neurologic event rate in patients undergoing
repeat surgery also were present, but, again, stroke or death
rates were not different. While the small number of patients
in this group precludes statistical analysis, it is notable that
91% of patients who required repeat surgery underwent
angiography and that two of the three neurologic events
(both transient ischemic attacks) in this group occurred
during angiography. No other criteria increased perioper-
ative risk.
DISCUSSION
On the basis of a mass of collected empiric data as well
as several large prospective randomized trials, surgical end-
arterectomy is widely accepted as the treatment of choice
for significant atherosclerotic disease at the carotid bifurca-
tion. With the increased interest in noninvasive interven-
tion, explosive growth in catheter-based techniques, and
increasing interest by non-surgeons in carotid disease, an-
gioplasty and carotid artery stenting have become increas-
ingly common. Published series so far suggest results that
are inferior to endarterectomy, with combined stroke and
death rates after carotid artery stenting in the 4% to 12%
range.1-7 Proponents of stenting legitimately point out that
many of these series incorporate procedures performed
without the benefit of cerebral protection devices, and a
favorable learning curve does seem to exist.5-7 While some
believe prospective randomized trials are appropriate, not
all agree that true equipoise has been reached, and it has
been proposed that carotid artery stenting be reserved only
for patients with carotid lesions who are at high risk.8,9,14
While this seems reasonable in theory, the definition of
high risk varies according to training and practice experi-
ence. It has been correctly emphasized that the inclusion
criteria for NASCET and ACAS, the two major prospective
randomized trials used for contemporary decision-making,
are fairly restrictive. Some have used this fact as a strategy to
define high risk for CEA and hence suitability for stenting,
but this does not follow logically. For example, while some
exclusion criteria (eg, previous radiation therapy to the
neck, significant coronary artery disease) would seem to
legitimately increase risk, others (eg, advanced age, repeat
surgery) do not seem to in our modern era. Further, a large
number of exclusion criteria (eg, atrial fibrillation, aspirin
allergy, other lesion that could cause similar symptoms) had
nothing to do with risk per se but were included to avert
difficulty in enrollment or assessment of outcome.
The concept of high risk for CEA has been specifically
explored in three recent reports. Ouriel et al9 identified a
group at high-risk for endarterectomy, defined as coronary
artery disease requiring angioplasty or CABG within 6
months preceding CEA, a history of congestive heart fail-
ure, severe chronic obstructive pulmonary disease, or renal
insufficiency with a creatinine concentration of 3.0 g/dL or
greater. Anesthetic technique was not reported. Using
these criteria, they documented stroke, death, or myocar-
dial infarction in 7.4% of the 19.4% of patients who met
these criteria, compared with only 2.9% of those who did
not (P  .0005). In this series, however, 13% of patients
underwent combined CEA and CABG, with clearly worse
outcome. Differences were still seen in patients at high risk
versus low risk undergoing CEA only, but these were less
robust and the composite end point difference (5.1% vs
2.9%, respectively) did not reach significance. In a similar
evaluation, Jordan et al15 reviewed their recent experience,
again classifying risk according to generally accepted high-
risk criteria without reference to prior specific study proto-
col criteria. Although a threefold increase in adverse out-
come rate was noted in patients undergoing combined
CEA and CABG, overall stroke and death rates were not
significantly different between high-risk and low-risk
groups otherwise. A substantially higher rate of cardiac
problems was found in patients with preexisting cardiac
dysfunction, but no adverse events occurred in 25 patients
undergoing repeat CEA or in a small number with ana-
tomic limitations and pulmonary dysfunction.
Finally, Lepore et al13 retrospectively reviewed 366
CEAs performed over 2 years with respect to NASCET and
ACAS criteria. They found that in the 169 patients who
would have been ineligible for NASCET or ACAS, results
Table IV. Specific complications: July 1993 to
December 2000 (n  859)
Complication n
Major



















Significant cranial nerve injury 6
Minor
Urinary retention, falls, minor
cranial nerve injury
45
Thirty-day complication rates for all patients analyzed during the study
period. Postoperative hemodynamic problems were judged minor if simply
noted in the chart or treated on the floor, and major if intensive care unit
transfer or delay in discharge was required. Major cranial nerve injuries were
defined as symptomatic injury to the hypoglossal, glossopharyngeal, or
vagus nerves.
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(ie, stroke or death) were not significantly different (3.6%)
from those in patients who would have been included
(1.5%; P  .17). Almost half (46%) of their patient popu-
lation would not have been eligible for one trial or the
other.
Our review focuses specifically on whether the various
exclusion criteria for NASCET and ACAS and inclusion
criteria for ARCHeR define a group at higher risk for CEA.
While trends, when present, almost always suggested
higher complication rates in groups at high risk, the abso-
lute differences were seldom as high as twofold (not statis-
tically significant) and, we believe, were clinically quite
similar. No differences in combined stroke or death rates
were noted between patients who would have been ex-
cluded or included in NASCET and ACAS trials or eligible
or ineligible for ARCHeR. The sole suggestive trend to-
ward support of this high-risk concept occurred in the
ARCHeR medical inclusion arm, in which 4.6% of those
eligible experienced stroke or died, compared with only
2.0% of those considered at low risk (P .11; Table VI). In
this category, the inclusion and high-risk criteria seem most
reasonable. For example, to be considered a patient must
meet at least two of the following criteria: greater than
two-vessel coronary disease not amenable to revasculariza-
tion, unstable angina, need for CABG or valve surgery
within 30 days, or myocardial infarction within 30 days.
Class III congestive heart failure (New York Heart Associ-
ation classification), ejection fraction less than 30%, or
forced expiratory volume in 1 s less than 30% predicted are
also eligibility criteria. These factors are quite similar to
those used by Ouriel et al,9 who did seem to define a true
subset of patients at high risk in their experience.
When looking at high-risk criteria independent of study
protocols, our patients older than 80 years had a higher
overall rate of complications (40.5% vs 30.4%; P  .02;
Table VII). This was most often due to urinary retention
(all incidences in patients operated on under general anes-
thesia) and falls, with a modest but nonsignificant increase
in postoperative hypertension and nonfatal cardiac events.
The combined stroke or death rates, however, again were
not statistically different. There were trends toward in-
creased overall neurologic events and overall complication
rates in patients undergoing repeat surgery, although the
number of patients in this group was too small for accurate
comparison. A large percentage of these patients under-
went preoperative angiography (91% vs 21% of the group
Table V. Outcome according to NASCET/ACAS criteria
P
Excluded (n372) Included (n487)
All patients (n  859) (%)
Stroke or death 2.7 1.6 .29
Any neurologic problem 4.8 3.7 .69
Any complication 34.9 30.0 .12
Patients excluded because of stroke or death rate
Excluded (n  34) Included† (n  825)
Anatomic criteria (%) 2.9 2.1 .73
Prior carotid endarterectomy (33)
Radiation therapy (1)
Excluded (n  242) Included† (n  617)
Medical criteria (%) 2.9 1.8 .39
Age 80 (%) (148)
Recent contralateral carotid endarterectomy (53)
Cardiac valvular disease (33)
Renal failure (15)
Other (10 each)
Excluded (n  163) Included† (n  696)
Protocol criteria (%) 3.1 1.9 .34
Warfarin sodium use (62)
Global symptoms (62)
Atrial fibrillation (18)
Recent contralateral symptoms (11)
Other (10 each)
Excluded (n  276) Included (n  583)
Medical or anatomic only (%) 2.9 1.7 .26
Thirty-day stroke or death (unless additionally noted) rates in all patients classified as to whether they would have been excluded from NASCET and ACAS
according to criteria as defined in text. Anatomic variables are those judged to make surgery more difficult, medical as those making surgery more risky, and
protocol as those that exclude a patient because of difficulty in enrollment or outcome assessment. Overall stroke or death rate for all patients eligible for
NASCET or ACAS was 1.6%, which was not significantly different from any subgroup. Groups were compared with 2 and Fisher exact tests; exact P values
are given.
*Patients in the excluded column are at high risk.
†In all subgroups those who meet the exclusion criteria are compared against those who would have been included based on the same criteria; subgroups
marked with a dagger thus comprise some patients who would have been excluded based on other criteria.
NASCET, North American Symptomatic carotid Endarterectomy Trial; ACAS, Asymptomatic Carotid Atherosclerosis Study.
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overall), and two of the three events, both transient isch-
emic attacks, occurred during angiography.
One’s definition obviously affects the percentage of
patients considered to be at high risk. For example, if the
generic concept of NASCET and ACAS exclusion is used,
43.3% of our patients would be considered at high risk, a
figure similar to that of the experience of Lapore et al.13
Even when patients who would have been excluded be-
Table VI. Outcome according to ARCHeR criteria
P
Eligible (n128) Ineligible (n675)
All patients (803†) (%)
Stroke or death 3.1 2.1 .40
Any neurologic problem 6.3 4.3 .33
Any complication 31.3 32.9 .88
Patients included because of stroke or death rate
Eligible (n  49) Ineligible‡ (n  754)
Anatomic criteria (%) 2.3 2.0 .98
Prior carotid endarterectomy (33)
High lesion (13)
Other (10 each)
Eligible (n  87) Ineligible (n  716)
Medical criteria (%) 4.6 2.0 .11
Contralateral occlusion (60)
Dialysis (12)
Coronary or valvular disease (10)
Other (10 each)
Eligible (n  18) Ineligible (n  785)
Hostile neck or severe carotid artery disease 11.1 2.1 .16
Thirty-day stroke or death rates (unless additionally noted) in all patients classified as to whether they would have been eligible for ARCHeR according to
criteria as defined in text. Anatomic variables are those judged to make surgery more difficult, and medical as those making surgery more risky. Overall stroke
or death rate for all patients excluded from ARCHeR was 2.1%, which was not significantly different from any subgroup. Groups were compared with 2 and
Fisher exact tests; exact P values are given.
*Patients in the eligible column are at high risk.
†Fifty-six patients would have been specifically excluded from consideration for ARCHeR; thus 803 patients were compared in this analysis.
‡In the anatomic and medical subgroups those who meet the inclusion criteria are compared against those who would not have been eligible based on the same
criteria; the subgroups marked with a double dagger thus comprise some patients who would have been included based on other criteria.
ARCHeR, Acculink for Revascularization of Carotids in High Risk Patients.
Table VII. Outcome according to specific high-risk factors*
P
Age (%) 80 (n  148) 80 (n  711)
Stroke or death 3.4 1.8 .23
Any neurologic problem 3.3 4.7 .37
Any complication 40.5 30.4 .02
Gender (%) Female (n  360) Male (n  491)
Stroke or death 1.7 2.4 .44
Any neurologic problem 3.9 3.9 .62
Any complication 32.8 32.8 .85
Repeat carotid endarterectomy (%) Repeat (n  33) Primary (n  826)
Stroke or death 3.0 2.1 .70
Any neurologic problem 9.0 3.3 .07
Any complication 21.2 32.6 .17
Contralateral occlusion (%) Yes (n  52) No (n  807)
Stroke or death 3.8 2.0 .36
Any neurologic problem 5.8 3.3 .36
Any complication 40.4 31.6 .19
Symptoms (%) Nonhemispheric (n  62) Focal or /Asx (797)
Stroke or death 3.2 2.0 .52
Any neurologic problem 3.2 3.5 .91
Any complication 38.7 31.6 .25
Thirty-day outcome in all patients classified as to whether they had various factors considered to be high risk for carotid endarterectomy. Groups were compared
with 2 and Fisher exact tests; exact P values are given.
*Patients in the first column are at high risk.
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cause of protocol reasons only were eliminated from this
group, 32.1% of patients would have been considered at
high risk according to this classification. By contrast, the
eligibility criteria for ARCHeR are stricter; only 15.9% of
our patients would have been eligible. A large number of
eligible patients, however, would be included on the basis
of an occluded contralateral artery. Elimination of these
patients yields a high-risk percentage of 8.5%, and if repeat
CEAs are also eliminated, essentially thus defining this
group in a post hoc sense as those with significant neck
problems or major medical problems only, the number
drops to 2.2% (18 of 803).
Our report, like all reports, should be interpreted with
its limitations in mind. Most important, this does not
include all patients operated on during this period, because
of lack of accurate data. Data availability did not seem to be
influenced by any of the criteria explored, and we believe
this approximates a (large) random sample of our overall
experience (Table II). Second, a large number of patients in
our study would have been excluded from NASCET and
ACAS only because of difficulty in enrollment or outcome
analysis (protocol criteria, Table V). While no statistically
significant differences existed, trends, when present, fa-
vored poorer outcome in patients at high risk. It is possible
that some of the factors we classified as protocol (eg,
warfarin sodium use, global symptoms, atrial fibrillation,
which together made up the bulk of this group) did,
indeed, increase risk.
Finally, because results of this report are largely nega-
tive, the possibility of a type II error must be considered.
When a type II error becomes a clinically insignificant result
depends on the amount of difference that really matters and
must be determined by each clinician in the context of the
individual problem. This study documents that in more
than 850 cases analyzed over 7 years no predictors of high
risk that reached statistical significance could be found.
Event rates in all groups, high risk and low risk alike, are low
and comparable with those of NASCET and ACAS. If
patients excluded from these trials are indeed at higher risk
than those included, such differences do not seem clinically
significant enough to justify recommending carotid artery
stenting over surgery in these groups at this time.
In summary, at our institution outcome was excellent
in patients who would have been excluded from the two
major prospective randomized trials or included in one
current high-risk stent registry. Whether analyzed accord-
ing to anatomic, medical, or protocol exclusion or inclusion
factors, such patients have neurologic and nonneurologic
outcome not significantly different from their included or
excluded cohorts. While groups at high risk may exist, the
premise that operative risk is higher in patients excluded
from NASCET and ACAS is not supported by our experi-
ence.
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